Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Appointments at Castle Biosciences, Oxford Nanopore, PGDx, More

Castle Biosciences: Kim Caple, Ellen Goldberg

Kimberlee Caple and Ellen Goldberg have been appointed to the board of directors of Castle Biosciences, effective immediately.

Caple is VP and general manager of Thermo Fisher Scientific's genetic sciences business. Prior to that, she was VP and general manager for Thermo Fisher's capillary electrophoresis business, and before that, VP of clinical business at Affymetrix. Caple holds a B.S. in biology from Purdue University.

Goldberg is the founder and president of Chord Consulting. Previously, she was VP of marketing at Crescendo Bioscience, and before that, she led marketing at Genomic Health. She has an M.S. in chemistry and an MBA from Stanford University, as well as a B.S. in chemistry from Yale University.

Oxford Nanopore Technologies: Wendy Becker, Adrian Hennah

Wendy Becker and Adrian Hennah have joined Oxford Nanopore Technologies' board of directors as independent non-executive directors, effective June 24.

Becker was previously CEO of clothing manufacturer and retailer Jack Wills, global chief marketing officer at Vodafone, managing director of TalkTalk, and a partner at McKinsey & Company. Later this year, she is expected to become chair of Oxford Nanopore's remuneration committee.

Hennah was previously CFO at Reckitt Benckiser, Smith & Nephew, and Invensys. Before that, he held senior management and financial positions at GlaxoSmithKline. He is expected to become chair of Oxford Nanopore's audit committee later this year.

Personal Genome Diagnostics: Mark Sausen

Personal Genome Diagnostics has appointed Mark Sausen as VP of technology innovation. Sausen previously spent six years as VP of research and development at PGDx and returns to the company from a stint as scientific director of clinical genetics and genomics at Bristol Myers Squibb. In his new role at PGDx, Sausen will lead the identification and development of new genomic sequencing technologies and applications to expand the firm's Elio product line.

Among other experience, Sausen has contributed to research at the Ludwig Center for Cancer Genetics and Therapeutics, the Helen F. Graham Cancer Center, and the Human Performance Laboratory. He holds a Ph.D. in cellular and molecular medicine from Johns Hopkins School of Medicine and has received numerous awards and research grants for his work in genomics and diagnostics.

For additional recent items on appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.